Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI.
Authors
Jakob Hagen Vasehus Schou
Departments of Oncology, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Jakob Hagen Vasehus Schou , Nicklas Roest , Morten Ladekarl , Jens Bo Rode Hansen , Maj Hedtjaern , Peter Michael Vestlev
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.185
Abstract #
185
Poster Bd #
M10
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.
First Author: Shigenori Kadowaki
Poster
2015 ASCO Annual Meeting
Genotype-directed phase II study of irinotecan dosing in metastatic colorectal cancer (mCRC) patients receiving FOLFIRI + bevacizumab: The GENIC study.
First Author: Grant Richard Williams
Poster
2011 Gastrointestinal Cancers Symposium
Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer.
First Author: Kentaro Yamazaki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.
First Author: Jonathan Matthew Hernandez